OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO Combined with KEYTRUDA for Late-Stage Metastatic Melanoma
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply Agreement with Merck to to evaluate the combination of OncoSec's DNA-plasmid interleukin-12
July 7, 2021
by firstwordpharma
Sirtex Medical announces collaboration update with OncoSec Medical
Sirtex Medical US Holdings, Inc. announced an advancement in its strategic collaboration with OncoSec Medical, Inc. relating to OncoSec's lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
January 20, 2021
by prnasia
OncoSec Announces Initiation of aStudy to Evaluate Melanoma Treatment
OncoSec Medical Incorporated announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D. of the H. Lee Moffitt Cancer Center and Research Institute and ...
August 31, 2020
by americanpharmaceuticalreview
OncoSec Releases Interim Data from Ongoing Study of TAVO, KEYTRUDA® Combo
OncoSec Medical has announced interim data from KEYNOTE-890, an ongoing Phase 2 study of TAVO™ (intratumoral IL-12) in combination with KEYTRUDA® in patients with heavily pretreated ...
May 23, 2019
by americanpharmaceuticalreview
OncoSec, Gynecologic Oncology Group to Conduct Study of TAVO with KEYTRUDA
OncoSec has established a collaboration with the GOG Foundation to conduct a registration-enabled study of TAVO (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150)......
January 9, 2019
by americanpharmaceuticalreview